Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William K Kelly

Showing results (1-10 of 64) with videos related to

Pageof 7
Sort By:
Urologic Oncology|November 17, 2009
Epothilones in prostate cancerWilliam K Kelly
The Urologic Clinics of North America|October 23, 2012
Targeting angiogenesis as a promising modality for the treatment of prostate cancerJianqing Lin, William K Kelly
The Journal of Urology|November 21, 2002
Editorial: States and state transitions are all that really matterHoward I Scher, William K Kelly
JAMA|December 8, 2011
Androgen deprivation therapy and competing risksWilliam K Kelly, Leonard G Gomella
Asian Journal of Andrology|February 26, 2013
Prostate cancer biomarker: a key field to exploreJianqing Lin, Hushan Yang, William K Kelly
The Urologic Clinics of North America|July 2, 2021
Overview of Prostate Cancer Genetic TestingThenappan Chandrasekar, William K Kelly, Leonard G Gomella
Expert Opinion on Investigational Drugs|November 30, 2002
Histone deacetylase inhibitors: from target to clinical trialsWilliam K Kelly, Owen A O'Connor, Paul A Marks
Current Cancer Drug Targets|October 31, 2015
Indoleamine 2,3-dioxygenase (IDO): Biology and Target in Cancer ImmunotherapiesSenthamil R Selvan, John P Dowling, William K Kelly, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 13, 2002
Quantifying the amount of variation in survival explained by prostate-specific antigenDavid A Verbel, Glenn Heller, William K Kelly, et al.
Urology|January 30, 2004
Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized diseaseJames A Eastham, William K Kelly, Gary D Grossfeld, et al.
Pageof 7

Showing results (1-10 of 64) with videos related to

Sort By:
Pageof 7
Urologic Oncology|November 17, 2009
Epothilones in prostate cancerWilliam K Kelly
The Urologic Clinics of North America|October 23, 2012
Targeting angiogenesis as a promising modality for the treatment of prostate cancerJianqing Lin, William K Kelly
The Journal of Urology|November 21, 2002
Editorial: States and state transitions are all that really matterHoward I Scher, William K Kelly
JAMA|December 8, 2011
Androgen deprivation therapy and competing risksWilliam K Kelly, Leonard G Gomella
Asian Journal of Andrology|February 26, 2013
Prostate cancer biomarker: a key field to exploreJianqing Lin, Hushan Yang, William K Kelly
The Urologic Clinics of North America|July 2, 2021
Overview of Prostate Cancer Genetic TestingThenappan Chandrasekar, William K Kelly, Leonard G Gomella
Expert Opinion on Investigational Drugs|November 30, 2002
Histone deacetylase inhibitors: from target to clinical trialsWilliam K Kelly, Owen A O'Connor, Paul A Marks
Current Cancer Drug Targets|October 31, 2015
Indoleamine 2,3-dioxygenase (IDO): Biology and Target in Cancer ImmunotherapiesSenthamil R Selvan, John P Dowling, William K Kelly, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 13, 2002
Quantifying the amount of variation in survival explained by prostate-specific antigenDavid A Verbel, Glenn Heller, William K Kelly, et al.
Urology|January 30, 2004
Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized diseaseJames A Eastham, William K Kelly, Gary D Grossfeld, et al.
Pageof 7